abstract |
The invention concerns quinazoline derivatives of the formula I wherein X<SUP>1 </SUP>is a direct link or a group such as CO, C(R<SUP>2</SUP>)<SUB>2 </SUB>and CH(OR<SUP>2</SUP>); wherein Q<SUP>1 </SUP>is phenyl, naphthyl or a 5- or 6-membered heteroaryl moiety and Q<SUP>1 </SUP>optionally bears up to 3 substituents; wherein m is 1 or 2 and each R<SUP>1 </SUP>may be a group such as hydrogen, halogeno and trifluoromethyl; and wherein Q<SUP>2 </SUP>may be phenyl or a 9- or 10-membered bicyclic heterocyclic moiety and Q<SUP>2 </SUP>optionally bears up to 3 substituents; or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and the use of their receptor tyrosine kinase inhibitory properties in the treatment of proliferative disease such as cancer. |